KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	MRTX1133 Sensitive: C2 – Inclusion Criteria MRTX1133 Sensitive : C2	MRTX1133 Sensitive: C2 – Inclusion Criteria MRTX1133 Sensitive : C2
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	MRTX1133 Sensitive: C2 – Inclusion Criteria MRTX1133 Sensitive : C2	MRTX1133 Sensitive: C2 – Inclusion Criteria MRTX1133 Sensitive : C2
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	RMC-9805 Sensitive: C2 – Inclusion Criteria RMC-9805 Sensitive : C2	RMC-9805 Sensitive: C2 – Inclusion Criteria RMC-9805 Sensitive : C2
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	avutometinib + defactinib Sensitive: C3 – Early Trials avutometinib + defactinib Sensitive : C3	avutometinib + defactinib Sensitive: C3 – Early Trials avutometinib + defactinib Sensitive : C3
KRAS G12D	Biliary Tract Cancer	KRAS G12D	Biliary Tract Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12D	Hepatocellular Cancer	KRAS G12D	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3

KRAS G12D

Associations